Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Genomic surveillance at scale is required to detect newly emerging strains at an early timepoint

Darcy Vavrek, Lucia Speroni, Kirsten J. Curnow, Michael Oberholzer, Vanessa Moeder, Phillip G. Febbo
doi: https://doi.org/10.1101/2021.01.12.21249613
Darcy Vavrek
1Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dvavrek{at}illumina.com
Lucia Speroni
1Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirsten J. Curnow
1Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Oberholzer
1Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa Moeder
1Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Phillip G. Febbo
1Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Genomic surveillance in the setting of the coronavirus disease 2019 (COVID-19) pandemic has the potential to identify emerging SARS-CoV-2 strains that may be more transmissible, virulent, evade detection by standard diagnostic tests, or vaccine escapes. The rapid spread of the SARS-CoV-2 B.1.1.7 strain from southern England to other parts of the country and globe is a clear example of the impact of such strains. Early discovery of the B.1.1.7 strain was enabled through the proactive COVID-19 Genomics UK (COG-UK) program and the UK’s commitment to genomic surveillance, sequencing about 10% of positive samples.1 In order to enact more aggressive public health measures to minimize the spread of such strains, genomic surveillance needs to be of sufficient scale to detect early emergence and expansion in the broader virus population. By modeling common performance characteristics of available diagnostic and sequencing tests, we developed a model that assesses the sampling required to detect emerging strains when they are less than 1% of all strains in a population. This model demonstrates that 5% sampling of all positive tests allows the detection of emerging strains when they are a prevalence of 0.1% to 1.0%. While each country will determine their risk tolerance for the emergence of novel strains, as vaccines are distributed and we work to end the pandemic and prevent future SARS-CoV-2 outbreaks, genomic surveillance will be an integral part of success.

Competing Interest Statement

DV, LS, KJC, MO, VM, and PGF are or were employees of and hold equity in Illumina, Inc.

Funding Statement

This study was funded by Illumina, Inc.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflicts of interest: DV, LS, KJC, MO, VM, and PGF are or were employees of and hold equity in Illumina, Inc.

  • Funding source: This study was funded by Illumina, Inc.

Data Availability

Questions on data availability can be directed to the corresponding author, Darcy Vavrek dvavrek{at}illumina.com

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted January 15, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Genomic surveillance at scale is required to detect newly emerging strains at an early timepoint
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Genomic surveillance at scale is required to detect newly emerging strains at an early timepoint
Darcy Vavrek, Lucia Speroni, Kirsten J. Curnow, Michael Oberholzer, Vanessa Moeder, Phillip G. Febbo
medRxiv 2021.01.12.21249613; doi: https://doi.org/10.1101/2021.01.12.21249613
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Genomic surveillance at scale is required to detect newly emerging strains at an early timepoint
Darcy Vavrek, Lucia Speroni, Kirsten J. Curnow, Michael Oberholzer, Vanessa Moeder, Phillip G. Febbo
medRxiv 2021.01.12.21249613; doi: https://doi.org/10.1101/2021.01.12.21249613

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3298)
  • Dentistry and Oral Medicine (365)
  • Dermatology (280)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1173)
  • Epidemiology (13384)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5157)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3274)
  • Health Policy (1143)
  • Health Systems and Quality Improvement (1193)
  • Hematology (432)
  • HIV/AIDS (1019)
  • Infectious Diseases (except HIV/AIDS) (14636)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (478)
  • Medical Ethics (127)
  • Nephrology (525)
  • Neurology (4930)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (886)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (727)
  • Orthopedics (282)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (544)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4218)
  • Public and Global Health (7512)
  • Radiology and Imaging (1708)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (498)
  • Sports Medicine (424)
  • Surgery (549)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)